NanJing Pharmaceutical Company Limited

Shanghai Stock Exchange 600713.SS

NanJing Pharmaceutical Company Limited Revenue for the year ending December 31, 2023: USD 7.55 B

NanJing Pharmaceutical Company Limited Revenue is USD 7.55 B for the year ending December 31, 2023, a 3.72% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

NanJing Pharmaceutical Company Limited Revenue for the year ending December 31, 2022 was USD 7.28 B, a 2.48% change year over year.
NanJing Pharmaceutical Company Limited Revenue for the year ending December 31, 2021 was USD 7.10 B, a 16.42% change year over year.
NanJing Pharmaceutical Company Limited Revenue for the year ending December 31, 2020 was USD 6.10 B, a 14.33% change year over year.
NanJing Pharmaceutical Company Limited Revenue for the year ending December 31, 2019 was USD 5.34 B, a 17.23% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shanghai Stock Exchange: 600713.SS

NanJing Pharmaceutical Company Limited

CEO	Mr. Liang Zhang
IPO Date	July 1, 1996
Location	China
Headquarters	Building A
Employees	4,903
Sector	Health Care
Industries Drugstores & Retail Pharmacies Pharmaceuticals Retail & Wholesale

Description

NanJing Pharmaceutical Company Limited engages pharmaceutical wholesale and retail businesses in China. It also operates approximately 510 pharmacy retail stores and an e-commerce platform. The company was founded in 1951 and is based in Nanjing, China.

Key trends

Past 5 years